Tamtam Try Tamtam free
Incyte logo

Incyte account plan

global biopharmaceutical company medicines

At a glance

Incyte is a Wilmington, Delaware biopharma company in hematology, oncology and immunology: FY2025 total revenues $5,141.2 million, 2,844 employees.

Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware that discovers, develops and commercializes therapeutics in three areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its anchor product is JAKAFI (ruxolitinib), whose patents expire in 2028, alongside the OPZELURA cream, NIKTIMVO, MONJUVI/MINJUVI, ZYNYZ, ICLUSIG and PEMAZYRE, plus royalties from Novartis and Eli Lilly. FY2025 total revenues were $5,141.2 million (FY2024: $4,241.2 million) and net income $1,286.7 million. It had 2,844 employees at year-end 2025, 70% in the U.S. and Canada, with European headquarters in Morges, Switzerland. William (Bill) Meury has been President and CEO since June 2025.

Business units

Strategic priorities

Offset JAKAFI exclusivity loss
The company says it must develop new products to offset the loss of JAKAFI exclusivity in 2028; it aims to retain 10%-30% of the Jakafi business by 2029 through Jakafi XR.
Scale the core business beyond Jakafi
Core business ex-Jakafi was $490 million in Q3 2026 (+30%); Meury sees it growing to $3 billion-$4 billion by 2030.
Late-stage pipeline execution
Six assets in Phase 3, including povorcitinib, INCA033989 (mutCALR), the KRAS G12D inhibitor and latarcibart; Meury says the risk managed is increasingly execution of Phase III programs.
Expand Opzelura
Deliberate 2026 investment in a bigger sales force, NP/PA promotion and formulary quality; the EU approved Opzelura for moderate AD in July 2026.
Business development
Meury views BD as "a multiplier"; Vega Therapeutics was acquired in July 2026 for $1.25 billion.

Latest results

Q3 2026 total revenue was $1.56 billion and total net sales $1.32 billion, each up 14% versus Q3 2025. Jakafi/Jakafi XR net sales were $827 million (+4%) with paid demand up 12%, Opzelura $255 million (+36%) and Hematology and Oncology $235 million (+38%). The quarter showed a GAAP net loss of $784.8 million because of a one-time $1.23 billion IPR&D expense for the Vega Therapeutics acquisition; nine-month GAAP net income was $104.1 million. Guidance for 2026 was raised to total net sales of $5,210-5,300 million, Opzelura $1,100-1,120 million and Hematology and Oncology $890-910 million, with Jakafi unchanged at $3,220-3,270 million. Cash and marketable securities were $3.9 billion at September 30, 2026.

Investments and deals

Vega Therapeutics acquisition
Acquired in July 2026 for $1.25 billion plus up to $750 million in sales milestones, adding latarcibart for von Willebrand disease (Phase 3 topline in early 2029).
Late-stage R&D
R&D expenses were $2,050.2 million in 2025; GAAP R&D excluding the Vega charge rose 11% in Q3 2026 on late-stage development.
Partnerships and licensing
Enable Injections enFuse on-body delivery license for INCA033989 (October 2025) and the Lilly baricitinib amendment with a $100.0 million upfront.
Novartis settlement
In May 2025 Incyte paid $280.0 million for disputed royalties and the royalty rate on future U.S. JAKAFI sales was cut by 50%.

Challenges and risks

JAKAFI dependence
JAKAFI was $3,092.5 million of 2025 revenues and its patents expire in mid and late 2028.
Drug pricing pressure
Medicare and Medicaid reforms, most favored nation proposals and PBM formulary control; an August 2026 CMS agreement aligned Medicaid Jakafi prices with other industrialized nations.
Pipeline attrition
Meury said "attrition is a fact of life"; CDK2 enrollment in platinum-resistant ovarian cancer was discontinued and prurigo nodularis development for ruxolitinib cream was paused.
Supply concentration
Manufacturing is largely outsourced, ruxolitinib raw materials come from Chinese suppliers, and ZYNYZ and NIKTIMVO each rely on one qualified API maker; a European supplier is being qualified.

What leadership says

“gives us the scale to navigate the 2029 transition and fund R&D”

Bill Meury, President and CEO · On the core business, Q3 2026 earnings call, October 29, 2026

“we view BD as a multiplier, a way to extend and strengthen the core”

Bill Meury, President and CEO · Q4 2025 earnings call, February 10, 2026

“We can't declare victory yet.”

Bill Meury, President and CEO · On the Phase 3 pipeline, Q3 2026 earnings call, October 29, 2026

“what we're solving for is the steepest possible growth curve post '29 and durable earnings and cash flow”

Bill Meury, President and CEO · Q4 2025 earnings call, February 10, 2026

Where a supplier can help

Clinical trial execution
Tied to the late-stage pipeline priority: CROs, site networks and trial technology that help enrol Phase 3 programs on time fit management's focus on execution.
Launch and commercial support
Tied to the Opzelura expansion and upcoming povorcitinib and Monjuvi launches: field force tools, patient access services (benefit verification, prior authorisations) and promotion fit the launch plan.
Supply chain diversification
Tied to the supply concentration challenge: additional qualified API and drug-product manufacturers would reduce single-source exposure.
Pricing and market access analytics
Tied to the drug pricing challenge: gross-to-net, rebate and access analytics support management of Medicaid and Medicare rules.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Incyte?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Incyte

What does Incyte do?

Incyte discovers, develops and sells medicines in hematology, oncology and inflammation and autoimmunity, including JAKAFI and the OPZELURA cream, and earns royalties on drugs licensed to Novartis and Eli Lilly.

What is Incyte's revenue?

FY2025 total revenues were $5,141.2 million; 2026 total net sales guidance is $5,210-5,300 million.

How many employees does Incyte have?

2,844 at December 31, 2025, up from 2,617 a year earlier.

Who leads Incyte?

William (Bill) Meury has been President and CEO since June 2025; Pablo Cagnoni is President and Head of R&D.

What is Incyte's strategy?

Scale the core business beyond Jakafi to $3 billion-$4 billion by 2030 and advance its late-stage pipeline to offset the 2028 loss of JAKAFI exclusivity.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)